Literature DB >> 6714281

Entero-hepatic cycling of methotrexate estimated by use of the D-isomer as a reference marker.

J Hendel, H Brodthagen.   

Abstract

The absorption and elimination kinetics of 4-amino-N10-methylpteroyl-D-glutamic acid (D-MTX), the optical isomer of methotrexate (L-MTX), were examined. Test doses of 10 mg D-MTX were administered i.v. and orally to nine patients and its plasma concentration and urinary excretion were followed. The plasma curves after an i.v. bolus injection of D-MTX declined strictly biexponentially and reached zero after about 16 h. The elimination rate constants were estimated as the terminal first order rate constants. The absorption of orally administered D-MTX, estimated by its 24 h urinary recovery, in all cases was less than 3% of the dose administered. The insignificant intestinal absorption made it possible to estimate the renal and biliary secretion rates of D-MTX from the overall elimination rate constant and from the fraction of the dose excreted in urine. In three of the patients, elimination rate constants both for D-MTX and L-MTX were obtained. The renal elimination rates of the two compounds were found to be nearly identical. The median ratio of biliary/renal excretion of D-MTX was 0.94 (range 0.41-1.50), which indicates extensive entero-hepatic cycling and active absorption of L-MTX at the therapeutic dose levels used in psoriasis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6714281     DOI: 10.1007/bf00546716

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Small intestine in psoriasis.

Authors:  S Shuster; A J Watson; J Marks
Journal:  Br Med J       Date:  1967-08-19

2.  Relationship between intracellular dihydrofolate reductase and tightly bound intracellular methotrexate in human neoplastic cells.

Authors:  R A Bender; D R Makulu
Journal:  Biochem Pharmacol       Date:  1976-04-15       Impact factor: 5.858

3.  Effect of route of administration and effusions on methotrexate pharmacokinetics.

Authors:  S H Wan; D H Huffman; D L Azarnoff; R Stephens; B Hoogstraten
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

4.  Polygammaglutamyl metabolites of methotrexate.

Authors:  C M Baugh; C L Krumdieck; M G Nair
Journal:  Biochem Biophys Res Commun       Date:  1973-05-01       Impact factor: 3.575

5.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

6.  Folic acid antagonists. Methotrexate analogs containing spurious amino acids. Dichlorohomofolic acid.

Authors:  W W Lee; A P Martinez; L Goodman
Journal:  J Med Chem       Date:  1974-03       Impact factor: 7.446

7.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

8.  The "induction" of leukocyte and erythrocyte dihydrofolate reductase by methotrexate. II. Clinical and pharmacologic studies.

Authors:  J R Bertino; A Cashmore; M Fink; P Calabresi; E Lefkowitz
Journal:  Clin Pharmacol Ther       Date:  1965 Nov-Dec       Impact factor: 6.875

9.  Production of Methotrexate antiserum in rabbits: the significance of immunogen solubility, hapten content, and mode of administration of the antibody response.

Authors:  J Hendel; L J Sarek
Journal:  Scand J Clin Lab Invest       Date:  1977-05       Impact factor: 1.713

10.  Tissue-specific synthesis of methotrexate polyglutamates in the rat.

Authors:  V M Whitehead; M M Perrault; S Stelcner
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

View more
  13 in total

Review 1.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Low-dose methotrexate therapy for hepatoblastoma.

Authors:  S D Weitman; G J Kato; J L Barbosa; B A Kamen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  Stereoselectivity in pharmacokinetics: a general theory.

Authors:  R H Levy; A V Boddy
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

5.  Stereoselective disposition of flurbiprofen in normal volunteers.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

Review 6.  Chirality. Clinical pharmacokinetic and pharmacodynamic considerations.

Authors:  E J Lee; K M Williams
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 7.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

Review 8.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

10.  Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.

Authors:  Vaishnavi Ganti; Ellen A Walker; Swati Nagar
Journal:  Biomed Chromatogr       Date:  2013-03-12       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.